commentary about Omontys on Fresenius' ( FMS ) or Takeda's ( OTC:TKPHF ) latest earnings calls and the cash burn at Affymax ( AFFY ), all lead us to believe that the end is Complete Story »
per share from $101, as we have slightly increased our assumptions for Aranesp and Epogen sales following the withdrawal of Affymax 's Omontys from the market. Amgen's global ESA sales saw high-single-digit declines in 2012, and we expect this high
By Seth Shaw : Investors in Affymax ( AFFY ) would like you to believe that ..... make a miraculous comeback and that Affymax will be a major winner. My belief is that the last AFFY article contained multiple factual
By Tim Gallagher : A trailblazing pioneer, Affymetrix ( AFFY ) got off largely under-the-radar in 1992, and came public with its IPO in June 1996. AFFX "blasted-off" like a rocket
(Reuters) - Drug maker Affymax Inc said it may consider selling itself or filing for bankruptcy among a range of strategic alternatives as it struggles with the recent recall of its sole commercial product, the anemia drug Omontys.
March 18 (Reuters) - Affymax Inc, which recalled its anemia drug Omontys in February, said it may consider selling itself or filing for bankruptcy among a range of strategic alternatives.
(Reuters) - Shares of Affymax Inc fell 85 percent after it said serious adverse reactions, including death, were reported among some of those using its sole commercial product, anemia drug Omontys.
Aranesp pressure was expected, and Epogen declines appear to be caused more by competition (albeit minimal) from Affymax 's AFFY Omontys and less from the decreased ESA usage due to bundled reimbursement that has plagued growth in previous quarters
operators DaVita DVA and Fresenius FMS, we think future biosimilar competition--as well as branded products like Affymax 's AFFY recently approved anemia drug Omontys--cloud Epogen's long-term prospects. We're forecasting continued double-digit